Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
Pfizer’s first drug candidate from its Seagen acquisition, sigvotatug vedotin, failed to meet primary endpoints in a Phase 3 nonsquamous NSCLC trial.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A Phase 3 clinical trial for sigvotatug vedotin did not demonstrate a significant improvement in overall survival for patients with advanced, pretreated nonsquamous non-small cell lung cancer (NSCLC). This candidate was among the assets Pfizer gained through its acquisition of Seagen.
Coverage from BioPharma Dive, CancerNetwork, OncLive, and Kalkine Media highlights the drug's inability to reach primary study objectives. Reporting emphasizes the setback this represents for the company’s oncology pipeline following the high-profile merger.
Future developments remain dependent on further announcements from Pfizer regarding the specific data from the trial. Coverage does not yet specify the company's next steps for the development or potential termination of the drug program.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1d ago.
Quick answers
What drug failed the clinical trial?
The trial failure involved sigvotatug vedotin, an antibody-drug conjugate.
Which patient group was studied?
The trial focused on patients with advanced, pretreated nonsquamous non-small cell lung cancer (NSCLC).
What was the result of the study?
The drug did not significantly improve overall survival compared to the control metrics.
Coverage (5)
- Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC Yahoo Finance · 1d ago
- Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media · 1d ago
- Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork · 1d ago
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive · 1d ago
- Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive · 1d ago
Topics
Related trends
NIKE, Inc. Announces Planned CFO Transition —
NIKE, Inc. has officially announced a leadership shift, appointing David Denton as its new Chief Financial Officer.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s lung cancer drug fails pivotal trial, sending shockwaves through biotech markets
Seattle scientists seek answers as colorectal cancer trends younger
Global research efforts intensify as medical data confirms a rising trend of early-onset colorectal cancer among younger adults.